Centessa Pharmaceuticals plc
CNTA
Classifica tra le azioni
#2958
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical... Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Prezzo delle azioni
$40.50
Ultima sincronizzazione: 2026-06-29
Capitalizzazione di mercato
$6.22B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
77.71%
Paese
GB
Scambia Centessa Pharmaceuticals plc (CNTA)
Categoria
Healthcare
Utile per Centessa Pharmaceuticals plc (CNTA)
Utile nel Mar 2026 TTM: $-249.37M
Secondo gli ultimi rapporti finanziari di Centessa Pharmaceuticals plc, gli utili attuali della società sono $-249.37M. Nel 2023, la società ha registrato un utile di $-176.14M, un aumento rispetto a agli utili del 2022, che erano di $-216.95M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Centessa Pharmaceuticals plc dal 2019 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-249.37M | 7.06% |
| 2024 | $-232.91M | 32.23% |
| 2023 | $-176.14M | -18.81% |
| 2022 | $-216.95M | -43.17% |
| 2021 | $-381.79M | 3,480.47% |
| 2020 | $-10.66M | 110.69% |
| 2019 | $-5.06M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -2,215.32% |
US
|
|
| $-3.09B | 1,137.94% |
US
|
|
| $-4.02B | 1,510.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -882.24% |
NL
|
